The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
| Study Name on ClinicalTrials.gov (link is external) |
Extension Study of Ataluren for Nonsense Mutation Cystic Fibrosis |
|---|---|
| Study Drug | Ataluren (PTC124®) |
| Type of Study Drug | CFTR Modulation |
| Study Title | A Phase 3 Extension Study of Ataluren (PTC124) in Subjects With Nonsense-Mutation-Mediated Cystic Fibrosis |
| Study Phase | 3 |
| Study Sponsor | PTC Therapeutics |
|
https://clinicaltrials.gov/ct2/show/NCT02456103 (link is external) |
|
| Participating ECFS-CTN sites | Belgium: Leuven France: Lyon, Montpellier, Roscoff, West-Paris (Necker) Germany : Berlin, Cologne, Munich Italy: Florence, Milan, Rome, Verona The Netherlands: Rotterdam Spain: Barcelona |
| Age | 6 Years and older |
-
Hello There! -
